Research analysts at Zacks Research lowered their FY2025 EPS estimates for shares of Haemonetics in a report released on ...
Haemonetics (NYSE:HAE – Get Free Report) had its target price cut by stock analysts at Needham & Company LLC from $108.00 to ...
Zacks Investment Research on MSN5d
Is it Apt to Retain HAE Stock in Your Portfolio for Now?Haemonetics Corporation’s HAE impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth.
BOSTON, Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James ...
BOSTON, March 3, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes ...
Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer As Chief Operating Officer, Chan will direct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results